title: Higher frequency of selective losses of HLA-A and -B allospecificities in metastasis than in primary melanoma lesions.
abstract: Expression of HLA class I molecules is essential for the recognition of tumor cells by CD8+ T cells. In this study, 48 bioptic samples of 42 patients in all stages of melanoma were investigated after short-time cultivation of tumor cells. To confirm melanocytic origin of cultured cells, samples were screened for mRNA expression of melanoma markers gp100, tyrosinase, MAGE-3, MelanA, and MUC18 by reverse transcriptase-polymerase chain reaction. Surface expression of specific HLA-A and -B allospecificities on melanoma cells were analyzed with a standard microcytotoxicity assay after stimulation with interferon (IFN)-alpha and compared with the background found in peripheral blood mononuclear cells from the corresponding patients. Immunohistochemistry and flow cytometry confirmed specific losses in cases where the appropriate monoclonal antibodies were available. The level of expression of HLA-I, HLA-II, and intercellular adhesion molecule 1 antigens on melanoma cells cultured in the presence or absence of IFN-alpha and IFN-gamma was determined cytofluorometrically. All cell cultures tested were found to be positive for one or more melanocytic markers by reverse transcriptase-polymerase chain reaction. The specific HLA-I alleles on the cultured cells were detectable in 45 of 48 samples. In 11 cases a specific loss of one HLA-I allele was observed (2 x A2, B7, B8, B18, 4XB44, B47, B49). Ten of these samples were derived from locoregional lymphnode metastases or from distant metastatic tumors. Only one sample from a primary melanoma showed a specific loss of HLA-I (B47). IFN-alpha upregulated expression of HLA-I up to 4-fold. IFN-gamma enhanced the appearance of HLA-II up to 35-fold and the expression of intercellular adhesion molecule 1 up to 40-fold. Selective loss of HLA-I allospecificities might be a major step in tumor progression.
authors.affiliation: Department of Dermatology, University Hospital, Zürich, Switzerland.
authors.forename: R C
authors.initials: RC
authors.lastname: Geertsen
authors.forename: G F
authors.initials: GF
authors.lastname: Hofbauer
authors.forename: F Y
authors.initials: FY
authors.lastname: Yue
authors.forename: S
authors.initials: S
authors.lastname: Manolio
authors.forename: G
authors.initials: G
authors.lastname: Burg
authors.forename: R
authors.initials: R
authors.lastname: Dummer
mesh_terms: D000937:Antigen-Antibody Reactions; D000951:Antigens, Neoplasm / Q000032:analysis; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes; D005434:Flow Cytometry; D015234:HLA-A Antigens / Q000276:immunology*; D015235:HLA-B Antigens / Q000276:immunology*; D006801:Humans; D007150:Immunohistochemistry; D016130:Immunophenotyping; D018799:Intercellular Adhesion Molecule-1 / Q000096:biosynthesis; D008545:Melanoma / Q000276:immunology* / Q000556:secondary; D016133:Polymerase Chain Reaction / Q000379:methods; D014158:Transcription, Genetic; D014407:Tumor Cells, Cultured
chemical_list: D000951:Antigens, Neoplasm; D000939:Epitopes; D015234:HLA-A Antigens; D015235:HLA-B Antigens; D018799:Intercellular Adhesion Molecule-1